Red Flags When a Centre Recommends Immunotherapy — What Should Make You Pause

Urgency without a reason. A price quoted before a biomarker report exists. A plan that changes when you mention insurance. A second opinion discouraged. Vague answers about who manages a side effect at night. None of these proves bad intent on its own. Each is a reason to slow down and ask for the recommendation in writing.

Immunotherapy sits at a price point where the stakes of a wrong recommendation are financial as well as medical. A family can spend a large part of its savings on a treatment that was never likely to help, and then have nothing left for the treatment that would have. That is the risk this page is about. It is not an accusation against any hospital, and this page does not rank or compare named centres. It is a set of things you are entitled to check before you agree.

A confirmed tissue diagnosis comes first. Then staging imaging, the biomarker tests that apply to your cancer type and line of treatment, baseline organ-function and thyroid bloods, and a documented autoimmune, transplant and steroid history. A recommendation made before the report that guideline bodies rely on is a recommendation made too early.

• Histopathology confirming the cancer and its subtype. A tissue diagnosis, reported and in your hands. Cytology alone is often not enough material for the biomarker work that follows.
• The biomarker test that applies to your cancer. Depending on the tumour and the line of treatment this may be PD-L1 expression reported as TPS or CPS, MSI-high or mismatch-repair-deficient status, or tumour mutational burden. NCCN, ESMO and ASCO all tie checkpoint-inhibitor use to defined biomarker and indication criteria. Which test applies is a clinical decision — so ask which one was done, and what it showed.
• Staging imaging, reported, and kept as the baseline. Later scans are read against it. At CION, response-assessment PET-CT is coordinated at partner imaging centres rather than owned by us, and those scans are billed by the imaging centre directly.
• Baseline bloods. Liver and kidney function, thyroid function, blood counts and glucose, before the first cycle. These are the values every later result is compared against.
• Autoimmune, transplant and steroid history, written down. Active autoimmune disease, an organ transplant or ongoing high-dose steroids can make a checkpoint inhibitor unsuitable or higher-risk. This has to be asked about, not assumed.
• A multidisciplinary review, not one doctor’s view. A tumour board is where an expensive, long-running plan should be tested against alternatives before anyone is asked to pay for it.

Worth saying plainly, because it is the part most often left out: most patients in India who ask about immunotherapy turn out not to be candidates for it, once the cancer type, stage, biomarker result and general fitness are all considered. A centre that tells you this early is not being negative. It is being accurate, and it is saving you the money you may need later.

Before the first cycle, whenever the recommendation is not written down, not tied to a named test result, or not itemised on cost. Also when you are told there is no alternative, when a second opinion is discouraged, or when the plan has no stated stopping point. Asking is routine and changes nothing about your care.

1. 1

   The recommendation is verbal only

   Ask for it in writing: the drug, why it is indicated for you, how many cycles, and what happens if it does not work.

2. 2

   No biomarker report has been shown to you

   If the test that supports the decision has not been done, or has not been shared, the decision cannot be checked by anyone — including a second doctor.

3. 3

   You are told there is no alternative

   There is almost always more than one path, and one of them is not treating with this drug. A plan that never mentions the alternatives has not really presented a choice.

4. 4

   The cost is a single number with no breakdown

   Ask for an itemised, dated estimate — drug and dose per cycle, number of cycles covered, day care, monitoring bloods, imaging and what treating a side effect would add.

5. 5

   Nobody will say when treatment would stop

   Ask what would count as it working, what would count as it not working, and at what point the plan changes. An open-ended course with no review point is a financial risk as well as a clinical one.

Taking your reports to another oncologist is ordinary practice, and no reasonable team objects to it. If you want the questions written out in a form you can carry from desk to desk, see Questions to Ask a Centre Before Starting Immunotherapy, and How to Choose a Centre for Immunotherapy for the capability checklist behind them.

Because the amounts involved are large and the eligibility rules are technical. A family rarely has the information to judge whether a checkpoint inhibitor is the right choice, and the cost of getting it wrong is measured in months of income. That gap is what makes plain, checkable questions so useful.

Nothing here implies that any particular centre acts badly. Most do not. But an honest look at the situation says this: immunotherapy is expensive, it is prescribed in a system where a hospital earns more when it is prescribed, and the patient is usually the least-informed person in the room. Those three facts together are enough to justify caution, without anyone behaving improperly at all.

The protection is not suspicion. It is documentation. A written recommendation, a named test result, an itemised and dated estimate, and a stated review point are all things a good team produces willingly — and all things that make an unsupported recommendation visible immediately. Ask for them early, when refusing is still easy, rather than three cycles in when the money is already spent. Costs quoted anywhere in this process are indicative, as of the date on the estimate.

One practical safeguard costs nothing: keep your own file. Every report, every bill, every consent form, every discharge summary. It is what makes a second opinion possible in a day rather than a fortnight. See Getting Your Treatment Records and Reports for how to ask for records and what a complete file should contain.

It names the test result it rests on. It says what proportion of patients in your situation are expected to benefit, in the words the guidelines use. It states the cycles, the review point and the stopping rules. It is itemised on cost. And it says out loud what happens if the treatment does not work.

• It starts with eligibility, not benefit. The conversation opens with whether you are a candidate at all, and is willing to end there. Most patients who ask about immunotherapy are not candidates for it.
• It points to a report. “Your MSI result is this” or “your PD-L1 score is this, which is why this is indicated at this line” — with the report in front of you, not summarised from memory.
• It describes benefit in proportions, not promises. Checkpoint inhibitors help some patients considerably and do little for others. A team that describes it that way is describing it accurately.
• It has a stopping point. A planned number of cycles, a scheduled response assessment, and an agreed answer to what happens if the scan does not show what was hoped for.
• It is itemised and dated. Drug and dose per cycle, cycles covered, day-care charges, monitoring bloods, imaging, review consultations, and what an immune-related side effect would add as an outpatient and as an admission — indicative, as of the date it carries.
• It names who manages what goes wrong. A treating oncologist, an after-hours number that reaches a clinician, and a written escalation route to a named hospital if admission is needed.

At CION, immunotherapy is administered as day care — you come in, are treated, and go home the same day. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by us. Ask every centre you approach, including ours, to be equally specific about what it does itself and what it sends out. For district families weighing travel against capability, Immunotherapy Access From Districts of Telangana and Andhra Pradesh and Shared Care: Infusion in the City, Monitoring Near Home set out the realistic options. Travel times are indicative.

Treat a casual offer as a red flag and ask for the accreditation. CAR-T and other cell therapies are not the same as checkpoint-inhibitor immunotherapy, and in India they are delivered by a small number of accredited centres. CION does not provide CAR-T or cell therapy and does not stock CAR-T product.

The difference is the machinery around the treatment. A checkpoint inhibitor is an antibody given as a day-care infusion. CAR-T involves collecting a patient’s own immune cells, having them modified in a manufacturing facility, and returning them under inpatient monitoring — because the reactions that can follow, including cytokine release syndrome and neurological effects, have to be managed on site and quickly. That is why accreditation, not enthusiasm, decides which centres can offer it.

Our role here is orientation and onward referral: explaining what is involved, what to ask an accredited centre, and helping you get your records there in a usable form. Nothing on this page should be read as CION administering, stocking or arranging CAR-T product.

Three practical follow-ons. Where treatment can realistically happen if you live outside Hyderabad. How infusion in the city and monitoring near home can be split. And how to build the record file that makes a second opinion take a day instead of a fortnight.

• Immunotherapy Access From Districts of Telangana and Andhra Pradesh — what is available where, and how to weigh distance against the capability to manage side effects. Travel times indicative.
• Shared Care: Infusion in the City, Monitoring Near Home — when part of the monitoring can happen closer to home, and what has to be agreed for that to be safe.
• Getting Your Treatment Records and Reports — what a complete file contains, how to ask for it, and why holding your own copies protects you.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring between cycles and cost counselling fit together as one pathway.

A Good Team Will Not Mind You Checking

Written recommendation, named test result, itemised dated estimate, stated stopping point. Asking for these is normal, and it changes nothing about your care.